Form 4: SOPHiA GENETICS Executive Sells Shares for Tax Withholding

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong sold 17,685 ordinary shares to cover tax obligations related to vested restricted stock units, executing the sale under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jurgi Camblong, Executive Chairman of SOPHiA GENETICS SA, sold 17,685 ordinary shares on July 7, 2026.
• The sale was conducted to satisfy tax withholding obligations associated with the vesting of restricted stock units on July 3, 2026.
• These transactions were executed under a Rule 10b5-1(c) trading plan, indicating they were pre-arranged and not discretionary.
• Following the sale, Camblong beneficially owns 3,541,122 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine transaction for tax purposes under a pre-arranged plan, not indicative of a change in the executive's confidence in the company's future.

Positives

• The sale was executed under a Rule 10b5-1(c) trading plan, which is designed to comply with safe harbor provisions and demonstrates adherence to good corporate governance practices.
• The transaction was for tax withholding purposes, a common and expected event for executives receiving equity compensation.
• The reporting person retains a significant beneficial ownership of 3,541,122 ordinary shares.

Negatives

• A portion of the executive's shares were sold, reducing their direct holdings.

Risks

• While the sale was pre-planned, any significant stock sales by insiders can sometimes be perceived negatively by the market, regardless of the stated reason.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports on a past transaction.

Management Comments

• The sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes, especially when conducted under a Rule 10b5-1 plan, are a routine event in the biotechnology and healthcare technology sectors. This filing is typical for executives managing equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact, as the sale is for tax purposes and executed under a pre-planned strategy, not a reflection of negative sentiment towards the company's stock performance.
• Employees: No direct impact, other than reinforcing standard executive compensation practices.
• Management: Fulfills tax obligations related to equity compensation.

Next Steps

• Continued adherence to the Rule 10b5-1 trading plan for any future transactions.
• Ongoing management of equity awards and associated tax liabilities by company executives.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1, Executive Compensation, Beneficial Ownership